MAPRE3

Across TCGA pan-cancer cohorts, MAPRE3 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated MAPRE3 data layer compared with 4 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAPRE3 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MAPRE3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.

LUAD, MESO, and KIRP are the cancer types where MAPRE3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.451	0.288	<.001	59	view →
MESO	OS	Median	All	0.300	0.469	.007	55	view →
KIRP	DFS	Quartile	II,III,IV	0.498	0.880	.003	51	view →
THYM	OS	Median	All	0.678	1.000	<.001	30	view →
SKCM	OS	Median	All	0.420	0.269	.008	19	view →
STAD	OS	Tertile	IV	0.535	0.134	.006	12	view →
LUSC	DFS	Median	II,III,IV	0.716	0.354	.003	12	view →
PRAD	DFS	Quartile	All	0.724	0.881	.007	12	view →
COAD	OS	Median	IV	0.684	0.421	.033	11	view →
READ	DFS	Tertile	IV	0.322	0.757	.016	11	view →
LIHC	DFS	Tertile	All	0.486	0.642	.007	11	view →
GBM	OS	Tertile	All	0.227	0.353	.010	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

MAPRE3–LUAD (OS)

Open the LUAD breakdown →